Top

Published in:

01-06-2021 | Surgery | Original Article

Small Bowel PCI Score as a Prognostic Factor of Ovarian Cancer Patients Undergoing Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC), a Retrospective Analysis of 130 Patients

Authors: Christos Iavazzo, Alexandros Fotiou, Victoria Psomiadou, Sofia Lekka, Dimitrios Katsanos, John Spiliotis

Published in: Indian Journal of Surgical Oncology | Issue 2/2021

Abstract

Ovarian cancer is the leading cause of death among gynecologic malignancies. Combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) can benefit patients with advanced ovarian cancer. We evaluate the role of small bowel peritoneal cancer index (sb-PCI) score as a prognostic factor. We retrospectively analyzed characteristics and clinical outcomes of patients that underwent intermediate cytoreductive surgery combined with HIPEC after neoadjuvant chemotherapy and patient’s characteristics underwent debulking surgery plus HIPEC for recurrence disease. One hundred thirty patients were included. Eighty-five of them (65.4%) were treated for recurrent ovarian cancer, while 45 (34.6%) underwent intermediate cytoreductive surgery after neoadjuvant chemotherapy with a mean age of 52 years. Mean intraoperative peritoneal cancer index (PCI) was 11.84 with a mean sb-PCI score of 5.57. Univariate analysis revealed that PCI, sb-PCI, and completeness of cytoreduction (CC) were parameters that correlated significantly with overall survival, while after multivariate analysis sb-PCI and CC were identified as independent prognostic factors of survival. A statistically significant correlation between sb-PCI score and overall survival of patients with advanced ovarian cancer was revealed. Further larger future studies are required to confirm our conclusion in order to change the treatment of advanced ovarian cancer patients.

Ahmed SA, Abou-Taleb H, Yehia A, el Malek NAA, Siefeldein GS, Badary DM, Jabir MA (2019) The accuracy of multi-detector computed tomography and laparoscopy in the prediction of peritoneal carcinomatosis index score in primary ovarian cancer. Acad Radiol 26(12):1650–1658CrossRef

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRef

Whitwell HJ, Worthington J, Blyuss O, Gentry-Maharaj A, Ryan A, Gunu R, Kalsi J, Menon U, Jacobs I, Zaikin A, Timms JF (2020) Improved early detection of ovarian cancer using longitudinal multimarker models. Br J Cancer 122(6):847–856CrossRef

Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RHM, van der Burg MEL, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GCE, Pecorelli S, Reed NS (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953CrossRef

van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS (2018) Hyperthermic Intraperitoneal chemotherapy in ovarian Cancer. N Engl J Med 378(3):230–240CrossRef

Fotopoulou C, Sehouli J, Mahner S, Harter P, van Nieuwenhuysen E, Gonzalez-Martin A, Vergote I, Chiva L, du Bois A (2018) HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer? Ann Oncol 29(8):1610–1613CrossRef

Lim MC et al (2017) Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. J Clin Oncol 35(15_suppl):5520CrossRef

Muallem MZ, Sehouli J, Richter R, Babayeva A, Gasimli K, Parashkevova A (2020) Pre-operative serum CA125, peritoneal cancer index and intra-operative mapping score as predictors of surgical results in primary epithelial ovarian cancer. Int J Gynecol Cancer 30(1):62–66CrossRef

Sugarbaker PH (2015) Management of peritoneal metastases - basic concepts. J Buon 20(Suppl 1):S2–S11

10.

Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D, Baert T, Banerjee S, Belaroussi I, Blecharz P, Bruchim I, Cibula D, Colombo N, Concin N, Davidson B, Dashora A, Devouassoux-Shisheboran M, du Bois A, Ferrero A, Glasspool R, González-Martin A, Heinzelmann-Schwarz V, Joly F, Kim JW, Kridelka F, Ledermann J, Lorusso D, Mahner S, McCluggage WG, McNeish I, Mikami M, Mirza MR, Morice P, Nicum S, Olbrecht S, O’Donnell DM, Pautier P, Planchamp F, Pignata S, Querleu D, Ray-Coquard I, Rodolakis A, Sehouli J, Selcukbiricik F, Sessa C, Singh N, Tan DSP, Timmerman D, Tognon G, van der Velden J, Vergote I, Witteveen PO, Zeimet AG (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease dagger. Ann Oncol 30(5):672–705

11.

Mehta SS, Bhatt A, Glehen O (2016) Cytoreductive surgery and peritonectomy procedures. Indian J Surg Oncol 7(2):139–151CrossRef

12.

Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S (2015) Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22(5):1570–1575

13.

Coccolini F, Campanati L, Catena F, Ceni V, Ceresoli M, Jimenez Cruz J, Lotti M, Magnone S, Napoli J, Rossetti D, de Iaco P, Frigerio L, Pinna A, Runnebaum I, Ansaloni L (2015) Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. J Gynecol Oncol 26(1):54–61CrossRef

14.

Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H (2019) Ovarian cancer in the world: epidemiology and risk factors. Int J Women's Health 11:287–299CrossRef

15.

Yang WL, Lu Z, Bast RC Jr (2017) The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn 17(6):577–591CrossRef

16.

Junor EJ, Hole DJ, McNulty L, Mason M, Young J (1999) Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol 106(11):1130–1136CrossRef

17.

JV M (1934) Tumors of the female pelvic organs. Macmillan, New York

18.

Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101–104PubMed

19.

du Bois A et al (2004) Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16(Suppl 8):viii7–viii12

20.

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–1259CrossRef

21.

Fader AN, Rose PG (2007) Role of surgery in ovarian carcinoma. J Clin Oncol 25(20):2873–2883CrossRef

22.

Vergote I, de Wever I, Tjalma W, van Gramberen M, Decloedt J, van Dam P (1998) Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71(3):431–436CrossRef

23.

Paulsen T, Kjærheim K, KÆRN J, Tretli S, Tropé C (2006) Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer 16(Suppl 1):11–17CrossRef

24.

Martin-Camean M et al (2016) The role of surgery in advanced epithelial ovarian cancer. Ecancermedicalscience 10:666PubMedPubMedCentral

25.

Ramachandran A, Rajanbabu A, Bagul KG, Pavithran K, Vijaykumar DK (2018) Correlation of pattern of spread and outcomes in advanced epithelial ovarian cancers. Indian J Surg Oncol 9(2):126–132CrossRef

26.

Braicu EI, Sehouli J, Richter R, Pietzner K, Lichtenegger W, Fotopoulou C (2012) Primary versus secondary cytoreduction for epithelial ovarian cancer: a paired analysis of tumour pattern and surgical outcome. Eur J Cancer 48(5):687–694CrossRef

27.

Fotopoulou C, Richter R, Braicu EI, Schmidt SC, Lichtenegger W, Sehouli J (2010) Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients. Eur J Surg Oncol 36(12):1202–1210CrossRef

28.

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, Zhou Q, Iasonos A, Paul H, Hosaka M, Aghajanian CA, Leitao MM Jr, Gardner GJ, Abu-Rustum NR, Sonoda Y, Levine DA, Hricak H, Chi DS (2014) A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol 134(3):455–461CrossRef

29.

Pomel C, Jeyarajah A, Oram D, Shepherd J, Milliken D, Dauplat J, Reynolds K (2007) Cytoreductive surgery in ovarian cancer. Cancer Imaging 7:210–215CrossRef

30.

Sehouli J, Richter R, Braicu EI, Bühling KJ, Bahra M, Neuhaus P, Lichtenegger W, Fotopoulou C (2010) Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol 102(6):656–662CrossRef

31.

Deffieux X, Castaigne D, Pomel C (2006) Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. Int J Gynecol Cancer 16(Suppl 1):35–40CrossRef

32.

Chandramohan A, Thrower A, Shah N, Mohamed F (2017) Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre. Br J Radiol 90(1079):20170361CrossRef

33.

Mittal R, Chandramohan A, Moran B (2017) Pseudomyxoma peritonei: natural history and treatment. Int J Hyperth 33(5):511–519CrossRef

34.

Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, de Bree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N, Hartmann J, Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, Lamont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G, Society of Surgical Oncology Annual Meeting (2007) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 14(1):128–133CrossRef

35.

Elias D, Mariani A, Cloutier AS, Blot F, Goéré D, Dumont F, Honoré C, Billard V, Dartigues P, Ducreux M (2014) Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol 40(11):1467–1473CrossRef

36.

Rosendahl M, Harter P, Bjørn SF, Høgdall C (2018) Specific regions, rather than the entire peritoneal carcinosis index, are predictive of complete resection and survival in advanced epithelial ovarian cancer. Int J Gynecol Cancer 28(2):316–322CrossRef

37.

Benizri EI, Bernard JL, Rahili A, Benchimol D, Bereder JM (2012) Small bowel involvement is a prognostic factor in colorectal carcinomatosis treated with complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 10:56CrossRef

38.

Konigsrainer I et al (2014) Initial clinical experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in signet-ring cell gastric cancer with peritoneal metastases. J Gastric Cancer 14(2):117–122CrossRef

39.

Glehen O et al (2010) Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17(9):2370–2377CrossRef

Title: Small Bowel PCI Score as a Prognostic Factor of Ovarian Cancer Patients Undergoing Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC), a Retrospective Analysis of 130 Patients
Authors: Christos Iavazzo
Alexandros Fotiou
Victoria Psomiadou
Sofia Lekka
Dimitrios Katsanos
John Spiliotis
Publication date: 01-06-2021
Publisher: Springer India
Keywords: Surgery
Ovarian Cancer
Ovarian Cancer
Cytostatic Therapy
Peritoneal Cancer
Peritoneal Carcinomatosis
Published in: Indian Journal of Surgical Oncology / Issue 2/2021
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI: https://doi.org/10.1007/s13193-021-01304-w

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Small Bowel PCI Score as a Prognostic Factor of Ovarian Cancer Patients Undergoing Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC), a Retrospective Analysis of 130 Patients

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2021

An Initial Experience of Shoulder Resections and Reconstruction for Bone Tumours from a Cancer Centre in North-East India

Digital Breast Tomosynthesis: an Overview

The Association of Human Papillomavirus in Benign and Malignant Laryngeal Lesions—a Pilot Study

Minimally Invasive Esophagectomy the Standard of Care: Experience from a Tertiary Care Cancer Center from India

Pancreatic Cancer: “Whether to Cross the Border”?

Rotter’s Lymph Nodes—Do We Really Need to Remove During Axillary Clearance?